The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Rational Design of a Combination Medication for the Treatment of Obesity
Open accessAbstract
Existing obesity therapies are limited by safety concerns and modest efficacy reflecting a weight loss plateau. Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction. In vitro electrophysiologic experiments were conducted to determine the extent to which BUP+NAL stimulated hypothalamic pro‐opiomelanocortin (POMC) neurons in mouse brain. A subsequent study further characterized the effect of combination BUP+NAL treatment on food intake in lean and obese mice. Finally, a randomized, blinded, placebo‐controlled trial in obese adult subjects was conducted. Randomization included: BUP (300 mg) + NAL (50 mg), BUP (300 mg) + placebo (P), NAL (50 mg) + P or P+P for up to 24 weeks. BUP+NAL stimulated murine POMC neurons in vitro and caused a greater reduction in acute food intake than either monotherapy, an effect consistent with synergism. Combined BUP+NAL provided sustained weight loss without evidence of an efficacy plateau through 24 weeks of treatment. BUP+NAL completers diverged from NAL+P (P < 0.01) and P+P (P < 0.001) at week 16 and from BUP+P by week 24 (P < 0.05). The combination was also well tolerated. Translational studies indicated that BUP+NAL therapy produced synergistic weight loss which exceeded either BUP or NAL alone. These results supported the hypothesis that NAL, through blockade of β‐endorphin mediated POMC autoinhibition, prevents the classic weight loss plateau observed with monotherapies such as BUP. This novel treatment approach (BUP+NAL) holds promise for the treatment of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Actual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
Prevalence of Overweight and Obesity in the United States
Crespo, C. J., & Ellen, S. (2003) · Obesity: Etiology Assessment Treatment and Prevention · doi:10.5040/9781718206601.ch-001 · Cited by 4,379
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Self-citationRole of melanocortinergic neurons in feeding and the agouti obesity syndrome
Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., & Cone, R. D. (1997) · Nature · doi:10.1038/385165a0 · Cited by 1,902
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
Cause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542
Lignac, G. O. E. (1951) · PubMed · Cited by 1,013
Region-Specific Leptin Resistance within the Hypothalamus of Diet-Induced Obese Mice
Münzberg, H., Flier, J. S., & Bjørbæk, C. (2004) · Endocrinology · doi:10.1210/en.2004-0726 · Cited by 737
Bupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Stein, C. J., & Colditz, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0288 · Cited by 615
Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice
Lin, S., Thomas, T., Storlien, L., & Huang, X. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801209 · Cited by 568
Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons
Enriori, P. J., Evans, A. E., Sinnayah, P., Jobst, E. E., Tonelli-Lemos, L., Billes, S. K., Glavas, M. M., Grayson, B. E., Perello, M., Nillni, E. A., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.02.004 · Cited by 552
Self-citationStimulation of food intake by muscimol and beta endorphin
Grandison, L., & Guidotti, A. (1977) · Neuropharmacology · doi:10.1016/0028-3908(77)90019-3 · Cited by 528
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504
Bupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Hypothalamic Proopiomelanocortin Neurons Are Glucose Responsive and Express KATPChannels
Ibrahim, N., Bosch, M. A., Smart, J. L., Qiu, J., Rubinstein, M., Rønnekleiv, O. K., Low, M. J., & Kelly, M. J. (2003) · Endocrinology · doi:10.1210/en.2002-221033 · Cited by 351
Opioid peptides and the control of human ingestive behaviour
Yeomans, M. R., & Gray, R. W. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00041-6 · Cited by 317
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Self-citationSlinker, B. K. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0655 · Cited by 277
Midlife Body Mass Index and Hospitalization and Mortality in Older Age
Yan, L. L. (2006) · JAMA · doi:10.1001/jama.295.2.190 · Cited by 260
Croop, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830240090013 · Cited by 211
Duration of occupancy of opiate receptors by naltrexone.
Lee, M. C., Wagner, H. N., Tanada, S., Frost, J. J., Bice, A. N., & Dannals, R. F. (1988) · PubMed · Cited by 189
Endogenous opioids and feeding behavior: a 30-year historical perspective
Bodnar, R. J. (2004) · Peptides · doi:10.1016/j.peptides.2004.01.006 · Cited by 170
Holtzman, S. G. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90222-4 · Cited by 165
Effects of long-term therapy with naltrexone on body weight in obesity
Atkinson, R. L., Berke, L. K., Drake, C. R., Bibbs, M. L., Williams, F. L., & Kaiser, D. L. (1985) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1985.197 · Cited by 163
Self-citationTesting Whether an Identified Treatment Is Best
LASKA, E. M., & Meisner, M. (1989) · Biometrics · doi:10.2307/2531766 · Cited by 148
Combining sulfonylureas and other oral agents
Riddle, M. C. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00338-7 · Cited by 136
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Arnold, M. E., & Steinberg, C. M. (2000) · Obesity Research · doi:10.1038/oby.2000.53 · Cited by 116
Recant, L., Voyles, N. R., Luciano, M. G., & Pert, C. B. (1980) · Peptides · doi:10.1016/0196-9781(80)90008-x · Cited by 101
A controlled trial of naltrexone in obese humans.
Malcolm, R. J., O'Neil, P. M., Sexauer, J. D., Fe, R., Currey, H. S., & Counts, C. (1985) · PubMed · Cited by 97
Self-citationOpioids Hyperpolarize β-Endorphin Neurons via μ-Receptor Activation of a Potassium Conductance
Kelly, M. J., Loose, M. D., & Rønnekleiv, O. K. (2008) · Neuroendocrinology · doi:10.1159/000125597 · Cited by 85
Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study
King, A. C., Volpicelli, J. R., Gunduz, M., O’Brien, C. P., & Kreek, M. J. (1997) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1997.tb03856.x · Cited by 72
Acute dopamine/norepinephrine reuptake inhibition increases brain and core temperature in rats
Hasegawa, H., MEEUSEN, R. R., Sarre, S., Diltoer, M., Piacentini, M. F., & Michotte, Y. M. (2005) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00435.2005 · Cited by 70
Kalra, S. P., & Horváth, T. L. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb10698.x · Cited by 63
Billes, S. K., & Cowley, M. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301155 · Cited by 60
Self-citationNew Targets for Obesity Pharmacotherapy
Aronne, L. J., & Thornton-Jones, Z. D. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100163 · Cited by 53
Billes, S. K., & Cowley, M. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301526 · Cited by 48
Self-citationEvidence of interactions between melanocortin and opioid systems in regulation of feeding
Olszewski, P. K., Wirth, M. M., Grace, M. K., Levine, A. S., & Giraudo, S. Q. (2001) · Neuroreport · doi:10.1097/00001756-200106130-00042 · Cited by 48
Evolving strategies for the use of combination therapy in hypertension
Gradman, A. H., & Acevedo, C. (2002) · Current Hypertension Reports · doi:10.1007/s11906-002-0062-x · Cited by 46
Pelletier, G. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb19688.x · Cited by 43
Anorectic and behavioural effects of bupropion
Zarrindast, M. R., & Hosseini-Nia, T. (1988) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(88)90061-4 · Cited by 39
Strategies for Dealing with Multiple Treatment Comparisons in Confirmatory Clinical Trials
D’Agostino, R. B., Massaro, J. M., Russell, H. K., & Cabral, H. (1993) · Drug Information Journal · doi:10.1177/009286159302700307 · Cited by 24
The μ-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist
Zhang, J., Frassetto, A., Huang, R. R., Lao, J. Z., Pasternak, A., Wang, S.-P., Metzger, J. M., Strack, A. M., Fong, T. M., & Chen, R. Z. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.069 · Cited by 16
Weintraub, M. (1984) · Archives of Internal Medicine · doi:10.1001/archinte.1984.00350180055008 · Cited by 1
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Self-citationSLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Self-citationCellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
Metadata
- Authors
- Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D., Smith, D., Dunayevich, E., Tollefson, G. D., Weber, E., & Cowley, M. A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 17
- Issue
- 1
- Pages
- 30-39
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2144589456
- Cited by
- 345
- References
- 47
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.